Next Article in Journal
Systematic Analysis of Pharmaceutical Preparations of Chondroitin Sulfate Combined with Glucosamine
Next Article in Special Issue
Role of TRPM7 in Cancer: Potential as Molecular Biomarker and Therapeutic Target
Previous Article in Journal
Development of a Glycosaminoglycan Derived, Selectin Targeting Anti-Adhesive Coating to Treat Endothelial Cell Dysfunction
Previous Article in Special Issue
Modulation of TRP Channel Activity by Hydroxylation and Its Therapeutic Potential
Open AccessReview

Development of TRPM8 Antagonists to Treat Chronic Pain and Migraine

1
Pacific University School of Physical Therapy, Hillsboro, OR 97123, USA
2
One Amgen Center Dr, Thousand Oaks, CA 91320, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Susan M. Huang, Arpad Szallasi and Jean Jacques Vanden Eynde
Pharmaceuticals 2017, 10(2), 37; https://doi.org/10.3390/ph10020037
Received: 16 February 2017 / Revised: 16 March 2017 / Accepted: 23 March 2017 / Published: 30 March 2017
A review. Development of pharmaceutical antagonists of transient receptor potential melastatin 8 (TRPM8) have been pursued for the treatment of chronic pain and migraine. This review focuses on the current state of this progress. View Full-Text
Keywords: transient receptor potential melastatin 8 (TRPM*); pain; menthol; cold hyperalgesia; cold analgesia; mechanical hyperalgesia; migraine transient receptor potential melastatin 8 (TRPM*); pain; menthol; cold hyperalgesia; cold analgesia; mechanical hyperalgesia; migraine
MDPI and ACS Style

Weyer, A.D.; Lehto, S.G. Development of TRPM8 Antagonists to Treat Chronic Pain and Migraine. Pharmaceuticals 2017, 10, 37.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop